Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives $32.00 Average Price Target from Brokerages

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) has been given a consensus rating of “Moderate Buy” by the six research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $32.00.

Several equities research analysts recently issued reports on the stock. Wall Street Zen lowered shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 20th. Cantor Fitzgerald started coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “overweight” rating for the company. TD Cowen assumed coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued a “buy” rating for the company. Wedbush initiated coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $30.00 price objective for the company. Finally, Oppenheimer restated an “outperform” rating and set a $40.00 price objective on shares of Odyssey Therapeutics in a research report on Thursday, June 18th.

Insiders Place Their Bets

In other Odyssey Therapeutics news, major shareholder Sr One Capital Management, Llc sold 1,780 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $18.00, for a total transaction of $32,040.00. Following the sale, the insider directly owned 440,981 shares of the company’s stock, valued at $7,937,658. This trade represents a 0.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Tpg Gp A, Llc acquired 1,388,889 shares of the stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $25,000,002.00. Following the completion of the transaction, the insider directly owned 3,690,146 shares of the company’s stock, valued at approximately $66,422,628. This represents a 60.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 4,183,777 shares of company stock worth $75,319,986 in the last three months.

Odyssey Therapeutics Trading Down 3.2%

NASDAQ ODTX opened at $18.43 on Wednesday. The firm’s fifty day moving average is $17.51. Odyssey Therapeutics has a fifty-two week low of $15.10 and a fifty-two week high of $20.30.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its quarterly earnings results on Wednesday, June 17th. The company reported ($6.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.31) by ($5.46).